Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals is set to engage with investors at two key healthcare conferences in March 2024, including TD Cowen’s 44th Annual Health Care Conference in Boston and Leerink Partners Global Biopharma Conference in Miami Beach. The company plans to connect through one-on-one meetings and will be featured in a fireside chat and Q&A session at the former event, with a live webcast available online. Aurinia is known for its dedication to developing treatments for autoimmune diseases, notably introducing the first FDA-approved oral therapy for lupus nephritis in 2021.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
